DFMO Oral Treatment to Prevent Relapse in Patients Under 40 With Relapsed Ewing Sarcoma or Osteosarcoma After Therapy
Led by Montefiore Medical Center · Updated on 2026-05-14
15
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to determine if it is feasible to give DL-alpha-difluoromethylornithine DFMO to patients with relapsed Ewing sarcoma or osteosarcoma who have finished all planned treatments and show no signs of disease. These cancers often relapse, leading to poor outcomes, and DFMO, a synthetic analog of ornithine, has been studied in various cancers and approved by the FDA to reduce relapse risk in certain high-risk cancers. The study explores whether DFMO can help prevent recurrence in these patients.
Participants will receive DFMO orally twice daily in 28-day cycles. The dose depends on the patients body surface area, with tablets provided in specific amounts ranging from one to four tablets per dose. The tablets may be swallowed whole, chewed, or mixed with food or liquid. This treatment will continue for up to two years to assess feasibility and outcomes.
During the study, patients will be monitored for how well they tolerate DFMO and for any signs of cancer recurrence. Researchers will assess feasibility of administering DFMO and track event-free survival for up to two years. Patients need to meet specific health and recovery criteria before starting and will have regular assessments to monitor blood counts, kidney and liver function, and overall health throughout the study period.
CONDITIONS
Brief Title
DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
Research Team
R
Rebecca Zylber, MSN
L
Lara Fabish, MSN
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
DFMO Maintenance Therapy (Trial Intervention)
Observation Only (Current Care)
What it is
Oral DFMO maintenance, given after completion of all planned salvage therapy to patients with relapsed or refractory Ewing sarcoma or osteosarcoma who currently have no evidence of disease.
Observation (no further active therapy) following completion of relapse-directed treatment for relapsed Ewing sarcoma or osteosarcoma, with routine surveillance for recurrence.
Role in the study
Investigational maintenance regimen evaluated for feasibility and event-free survival after relapse therapy.
Standard practice: used as the baseline by which new post-relapse maintenance interventions are evaluated in cooperative group analyses.
Primary use
Used to evaluate whether ongoing oral DFMO following relapse therapy could help maintain remission in relapsed Ewing sarcoma or osteosarcoma.
Observation is used to monitor for relapse recurrence and direct further therapy if needed, without additional preventive treatment after salvage therapy.
How it is given or performed
DFMO is taken by mouth, with dose calculated according to body surface area, and given daily after relapse therapy is complete. Tablets may be swallowed, chewed, or crushed and mixed with food or liquid.
No active maintenance medication is given. Patients are monitored with regular follow-up and imaging for signs of disease recurrence, consistent with usual care after relapse therapy.
Evidence status
Results for DFMO maintenance are not yet established for this population; ongoing trial aims to evaluate feasibility and event-free survival. No published outcome results as of now.
Outcomes for observation after post-relapse therapy are reported in multiple cooperative group studies, though overall event-free survival remains limited for this high-risk population.
Important limitations
Unknown effectiveness and safety in this population; single-arm design limits direct comparison. Outcomes may differ from those in broader or mixed-age studies.
Current-care outcomes are generally poor; published data show limited long-term event-free survival for relapsed Ewing sarcoma or osteosarcoma after observation post-therapy. No post-relapse maintenance therapies have been proven in large randomized trials as of the cited publications.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 0 - 39Years
All Genders
Eligibility Criteria
You may qualify if you...
Patients younger than 40 years old at enrollment
Diagnosis of relapsed osteosarcoma or relapsed Ewing sarcoma with no evidence of disease after completing all planned therapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
At least 14 days since completing myelosuppressive chemotherapy
At least 21 days since last monoclonal antibody infusion with recovery to Grade less than 2 toxicity
At least 7 days since last biologic therapy not known to be myelosuppressive
At least 14 days since local external beam radiation therapy, at least 90 days since total body irradiation or craniospinal radiation, and at least 42 days since other substantial bone marrow radiation
Adequate bone marrow function with neutrophil count ≥ 750/microliter and platelet count ≥ 75,000/microliter
Adequate kidney function based on serum creatinine by age and gender
Adequate liver function with total bilirubin ≤ 1.5 times upper limit normal and SGPT (ALT) ≤ 5 times upper limit normal
You will not qualify if you...
Pregnant or breastfeeding females
Men and women of childbearing potential and their partners must agree to use effective contraception during the study
Patients with uncontrolled infection
Patients with significant ongoing serious medical problems unrelated to cancer that interfere with study treatment or increase toxicity risk
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 2 years
Participants take DFMO orally every 12 hours in 28-day cycles with dosage based on body surface area to help prevent disease recurrence.
Visits every 28 days for treatment cycles
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
DFMO Oral Treatment to Prevent Relapse in Patients Under 40 With Relapsed Ewing Sarcoma or Osteosarcoma After Therapy
Phase III Study of 177Lu-DOTATATE Lutathera with Olaparib for Treating Recurrent or Relapsed Solid Tumors in Children and Adolescents Expressing Somatostatin Receptors
Study of Tegavivint and Gemcitabine Combination Treatment in Patients Aged 1 to 30 Years with Relapsed or Refractory Osteosarcoma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group.
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.